Placebo News and Research

RSS

Pfizer announces that 14 abstracts for tofacitinib to be presented at ACR/ARHP annual meeting

Pfizer Inc. announced today that 14 abstracts for tofacitinib, an investigational oral Janus kinase (JAK) inhibitor for the treatment of adults with moderate-to-severe active rheumatoid arthritis (RA), will be presented at the American College of Rheumatology (ACR) / Association of Rheumatology Health Professionals (ARHP) 2012 Annual Meeting, which is being held November 9-14 in Washington, D.C.

18 Sep 2012

Thalidomide effective in treating disabling cough among people with idiopathic pulmonary fibrosis

In the first clinical trial to demonstrate an effective treatment for constant, disabling cough among people with idiopathic pulmonary fibrosis (IPF), researchers at the Johns Hopkins University School of Medicine found that taking thalidomide significantly reduced the cough and improved quality of life.

18 Sep 2012

Compelling data from two ITS Flunisyn Phase I clinical trials against multiple strains of influenza A

Immune Targeting Systems Limited, an emerging leader in the development of vaccines that promote T-cell responses against viruses and cancers, today announces compelling data from two Phase I clinical trials of FlunisynTM, the Company's lead vaccine programme which elicits potent immune responses against multiple strains of influenza-A virus.

18 Sep 2012

Antimuscarinics only moderately effective for overactive bladder

A comprehensive review of oral antimuscarinics for the treatment of overactive bladder concludes that the efficacy of treatment is, at best, moderate.

17 Sep 2012

Anthera to initiate blisibimod Phase 3 program for systemic lupus erythematosus

Anthera Pharmaceuticals, Inc., a biopharmaceutical company developing drugs to treat serious diseases associated with inflammation and autoimmune disorders, today provided an update on regulatory discussions for the global development of blisibimod.

17 Sep 2012

vasopharm's explorative phase IIa NOSTRA trial in TBI meets clinical endpoints for safety

vasopharm GmbH, a pharmaceutical company dedicated to the discovery and development of novel therapeutics for the treatment of cerebro- and cardiovascular diseases, today announces that the explorative phase IIa NOSTRA trial in Traumatic Brain Injury Patients met all clinical endpoints for safety and in addition demonstrated strong evidence of clinical benefit in patients.

17 Sep 2012

Positive results from Targacept TC-5619 Phase 2 trial for inattentive-predominant attention deficit/hyperactivity disorder

Targacept, Inc. today announced top-line results from a Phase 2 trial of TC-5619 as a treatment for inattentive-predominant attention deficit/hyperactivity disorder (ADHDi). In the trial, TC-5619 did not meet the primary outcome measure, change from baseline on the inattention subscale of the Conners' Adult ADHD Rating Scale-Investigator-Rated (CAARS-INV), after four weeks of treatment versus placebo.

17 Sep 2012

Study estimates drug concentrations of Truvada and tenofovir to reduce risk of HIV among MSM

Several large clinical trials have demonstrated that a daily oral dose of one or two antiretroviral drugs used to treat HIV infection can prevent infection in an approach known as pre-exposure prophylaxis, or PrEP.

15 Sep 2012

Insufficient evidence to support effectiveness of black cohosh for menopausal symptoms

Although many women coping with hot flashes and other distressing symptoms of menopause have turned to black cohosh supplements as a treatment alternative, a new review by The Cochrane Library finds no evidence that the herb is effective.

14 Sep 2012

Montelukast possible surgery alternative for obstructive sleep apnea

Leukotriene modifiers may provide a noninvasive treatment option for children with nonsevere obstructive sleep apnea, say researchers.

13 Sep 2012

Addition of sorafenib to chemotherapy does not prolong survival

The addition of sorafenib to gemcitabine/cisplatin fails to provide any additional benefit in chemotherapy-naïve patients with nonsquamous non-small-cell lung cancer, research shows.

13 Sep 2012

Glenmark's GBR 500 enters Phase II clinical development for severe ulcerative colitis

Glenmark Pharmaceuticals S.A. (GPSA), a wholly-owned subsidiary of Glenmark Pharmaceuticals Limited (GPL), announced today that GBR 500 has entered Phase II clinical development.

13 Sep 2012

Sanofi Aventis receives FDA approval for Aubagio to treat relapsing forms of MS

The U.S. Food and Drug Administration today approved Aubagio (teriflunomide), a once-a-day tablet for the treatment of adults with relapsing forms of multiple sclerosis (MS).

13 Sep 2012

Genzyme receives FDA approval for AUBAGIO to treat relapsing forms of MS

Genzyme, a Sanofi company, announced today that the U.S. Food and Drug Administration (FDA) has approved AUBAGIO (teriflunomide) as a new once-daily, oral treatment indicated for patients with relapsing forms of multiple sclerosis (MS).

13 Sep 2012

Breakthrough for dengue vaccine development

A live-attenuated vaccine against the four strains of dengue virus known as CYD-TDV has demonstrated promising efficacy in a phase IIb trial.

12 Sep 2012

Acupuncture therapy remains a prickly matter

Acupuncture may actually be effective for treating some types of chronic pain, a systematic review in the Archives of Internal Medicine shows.

12 Sep 2012

Transcept completes enrollment in TO-2061 Phase 2 trial for obsessive compulsive disorder

Transcept Pharmaceuticals, Inc. today announced that it has completed enrollment in its Phase 2 clinical trial evaluating TO-2061 added as adjunctive therapy for patients with obsessive compulsive disorder (OCD) who have not adequately responded to first-line treatment with an approved OCD medication.

12 Sep 2012

Daily low-dose inhaled corticosteroids do not benefit asthmatics

For two decades, asthma treatment for millions of people with a milder form of the disease has consisted of daily inhaled steroid medicine to reduce inflammation. Now, a new study has found that asthmatics who take the low-dose medication as a daily routine do no better than those who turn to their inhalers only when they have symptoms.

12 Sep 2012

Researchers present new results from RV144 HIV vaccine trial at AIDS Vaccine 2012

"A paper published in Nature on Monday sheds light on how a vaccine can turn the immune system against [HIV] and so offer protection from infection," Nature News reports, noting "[t]he results are also being presented at the AIDS Vaccine 2012 conference in Boston, Massachusetts, this week."

12 Sep 2012

KaloBios commences KB003 Phase 2 trial in severe asthma

KaloBios Pharmaceuticals, Inc. today announced that dosing has begun in a randomized, double-blind, placebo-controlled Phase 2 clinical trial of KB003, the company's anti-GM-CSF Humaneered monoclonal antibody, in subjects with severe asthma uncontrolled by corticosteroids.

12 Sep 2012

Placebo News and Research

Pfizer announces that 14 abstracts for tofacitinib to be presented at ACR/ARHP annual meeting

Thalidomide effective in treating disabling cough among people with idiopathic pulmonary fibrosis

Compelling data from two ITS Flunisyn Phase I clinical trials against multiple strains of influenza A

Antimuscarinics only moderately effective for overactive bladder

Anthera to initiate blisibimod Phase 3 program for systemic lupus erythematosus

vasopharm's explorative phase IIa NOSTRA trial in TBI meets clinical endpoints for safety

Positive results from Targacept TC-5619 Phase 2 trial for inattentive-predominant attention deficit/hyperactivity disorder

Study estimates drug concentrations of Truvada and tenofovir to reduce risk of HIV among MSM

Insufficient evidence to support effectiveness of black cohosh for menopausal symptoms

Montelukast possible surgery alternative for obstructive sleep apnea

Addition of sorafenib to chemotherapy does not prolong survival

Glenmark's GBR 500 enters Phase II clinical development for severe ulcerative colitis

Sanofi Aventis receives FDA approval for Aubagio to treat relapsing forms of MS

Genzyme receives FDA approval for AUBAGIO to treat relapsing forms of MS

Breakthrough for dengue vaccine development

Acupuncture therapy remains a prickly matter

Transcept completes enrollment in TO-2061 Phase 2 trial for obsessive compulsive disorder

Daily low-dose inhaled corticosteroids do not benefit asthmatics

Researchers present new results from RV144 HIV vaccine trial at AIDS Vaccine 2012

KaloBios commences KB003 Phase 2 trial in severe asthma

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo

Advancing Intracellular Delivery with LumiPore®

Latest News